Merck Prestige® EHV 1/4 Equine Vaccine 10 mL/10 Dose

Merck Prestige® EHV 1/4 Equine Vaccine 10 mL/10 Dose

Indications

This product has been shown to be effective for the vaccination of healthy horses 6 months of age or older against EHV-1 and EHV-4. Duration of immunity has not been established. For more information regarding safety and efficacy data, go to productdata.aphis.usda.gov. This product has been shown to be effective against virus shredding of EHV‐1 and EHV‐4.

• EHV-1 and EHV-4, or rhino, can cause respiratory tract infections. EHV 4 is typically associated with upper respiratory disease in younger horses. EHV-1 can cause respiratory disease, late-term abortions, early foal deaths, neurologic disease
• A combination of inactivated, purified, concentrated, adjuvanted, equine tissue culture origin equine herpesviruses types 1 and 4 (EHV-1 and EHV-4).
• Exceptional safety profile with the smooth Havlogen^® adjuvant
• Advanced filtration process through the Antigen Purification System (APS^™)

• DOSE:
• For primary vaccination aseptically administer 1 mL intramuscularly, repeat with a single dose in 4 - 6 weeks. Historically, annual revaccination with this product has been recommended. The need for this booster has not been established. For more information on revaccination frequency, consult your veterinarian.